Volume 13 Supplement 1

Proceedings of the 9th Edition of the Scientific Days of the National Institute for Infectious Diseases “Prof Dr Matei Bals”

Open Access

Hepatitis B coinfection in HIV-infected patients

  • Gabriela Jugănariu1, 2Email author,
  • Cristina Nicolau2,
  • Liviu Jany Prisăcariu2,
  • Carmen Manciuc1, 2,
  • Andra Teodor1, 2,
  • Cătălina Luca1, 2 and
  • Carmen Dorobăț1, 2
BMC Infectious Diseases201313(Suppl 1):P13

https://doi.org/10.1186/1471-2334-13-S1-P13

Published: 16 December 2013

Background

The similar routes of transmission for HIV and HBV infections place patients with either infection at greater risk for HIV/HBV co-infection. The aim of this study was to analyze the epidemiological, virological, immunological and evolutive characteristics of HIV-HBV coinfected patients in the Regional HIV/AIDS Center Iaşi.

Methods

We performed a retrospective study including 252 patients diagnosed with HIV associated with hepatitis B virus coinfection evaluated in the Infectious Diseases Hospital Iaşi between 2000-2013.

Results

HIV-HBV coinfection prevalence was 19.9%. We noticed a slightly higher frequency of coinfection in males (53.2%), most patients belonging to the age group 20-29 (86.5%), the median age of the group being 25.56 years. The predominant route of transmission was parenteral (57.5%), heterosexual being found in a significant proportion (40.1%). The mean CD4 cell count was 246.20 cells/cmm, over 41% of the cases had levels between 200-499 CD4 cells/cmm. Individual values of plasma HIV viral load varied from undetectable levels up to a maximum of 4,600,000 copies/mL, with a median value of 142,906 copies/mL. ALT levels in HIV and HBV coinfection varied between 10-323 U/L, the average being 49.90 U/L, more than 65% of subjects with pathological levels; 218% of the total cholesterol values were pathological, the mean for the group was 182.58 mg/dL. Only 16.8% in the coinfected group had serum triglyceride levels below the reference (160 mg/dL). All patients in the HIV-HBV coinfected group had antiretroviral therapeutic agents with dual action anti-HIV and anti-HBV, 87.3% receiving lamivudine alone or in coformulation; in a small number of cases (3.6%) we opted for tenofovir.

Conclusion

The liver injury in the context of coinfection with HBV remains a key issue in the management of patients with HIV infection and is a major cause of mortality and morbidity.

Authors’ Affiliations

(1)
“Gr.T.Popa” University of Medicine and Pharmacy
(2)
Infectious Diseases Hospital “Sf Parascheva”

Copyright

© Jugănariu et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement